The blockade of immune checkpoints in cancer immunotherapy
Drew, M. Pardolli
0
File not found
Nature Reviews Cancer
12, 252-264
2012
http://www.nature.com/nrc/journal/v12/n4/execsumm/nrc3239.html
RISK FACTORS
PATHOPHYSIOLOGY
- Antigens
- Apoptosis
- Autophagy
- Biomarkers
- Chemical Microenvironment
-
Cytokines
- An overview Cytokines
- Chemical Interactions
- Chemical Interactions
-
Interleukins
- alpha blockade
- An overview Interleukins
- anti-glycyl-tRNAsynthetase antibody (anti-EJ)
- anti-interferon-a monoclonal antibody
- Anti-interleukin-6 Receptor
- IL-4 and IL-13 relationship
- Interleukin 1-beta
- Interleukin 1-beta induced accumulation
- Interleukin 1alpha and MHC class1
- Interleukin-22 and CD5 blockade
- interleukin-27
- Interleukin-7 alpha-receptor
- Interleukin-9 and Antisynthetase Syndrome
- L-Selectin
- Mr16-1
- New Advances
- Receptors
- ST2 and interleukin-33
- th17 cells
- Toxin-interleukin-3 Conjugates
- Endocrine System
- immunoproeasomes
- Inflammation
- Interferons
- MHC major histocompatibility complex
- Muscle Damage Mechanisms
- Oxidative Stress
- Protein Interactions
REMEDIAL STEPS
- Home
- The blockade of immune checkpoints in cancer immunotherapy
